Update on the Treatment of Hepatitis B and Hepatitis C

To participate in this activity, please:

Course Credit:

1 AAFP Hour
1 AMA PRA Category 1 CreditTM
1 CA-BRN Contact Hour

Dates:

Opens: 2023-05-11
Closes: 2023-06-11

Target Audience:

Accreditation

In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The AAFP has reviewed Grand Rounds 2023, and deemed it acceptable for AAFP credit. Term of approval is from 01/05/2023 to 12/21/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1 contact hour.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Annenberg Center for Health Sciences

All members of the Eisenhower Health Education Committee have no relevant financial relationships to disclose

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Sammy Saab, MD, MPH

    Professor of Medicine and Surgery
    Medical Director, Pfleger Liver Institute
    Medical Director, Adult Liver Transplant Program
    Chief, Transplant Hepatology
    David Geffen School of Medicine, University of California, Los Angeles
    Los Angeles, California

Downloads

This course has no downloads at this time.

Learning Objectives

  • Utilize clinical, laboratory and imaging studies to help define the severity of liver disease
  • Describe evidence-based therapies for the pharmacologic treatment of hepatitis B and C
  • Develop management plan for patients infected with viral hepatitis in the context of its natural history and public health implications

Faculty Disclosures

Sammy Saab, MD, MPH

Dr. Saab is on the speakers bureau for AbbVie, Eisai, Exelixis, Gilead, Intercept, Mallinckrodt, Salix, Takeda

Dr. Saab does not intend to reference unlabeled, unapproved or investigational uses of products or devices in this presentation.